Hormonal
Oral administration of gut microbe-derived extracellular vesicles (EVs), specifically from Pseudomonas panacis, induces insulin resistance and glucose intolerance in skeletal muscle and adipose tissue by blocking the insulin signaling pathway (specifically pAKT) and inhibiting GLUT4 translocation.
This research suggests that the type of bacteria in your gut and the vesicles they release can directly impact your insulin sensitivity. A diet high in fat may alter your gut microbiome to produce more of these specific vesicles (from P. panacis), which then travel to your muscles and fat tissue to block insulin signaling. While this is a mouse study, it implies that maintaining a diverse, healthy gut microbiome through diet (fiber, fermented foods) might help prevent the production of these insulin-blocking vesicles, thereby supporting better glucose metabolism.
In vivo administration of stool EVs from high fat diet (HFD)-fed mice induced insulin resistance and glucose intolerance compared to regular diet (RD)-fed mice... P. panacis EVs blocked the insulin signaling pathway in both skeletal muscle and adipose tissue. Moreover, isolated P. panacis EVs induced typical diabetic phenotypes, such as glucose intolerance after glucose administration or systemic insulin injection.
Why this rating
The study uses murine models (mice) and in vitro cell lines (L6 myotubes, 3T3-L1 adipocytes). While the mechanisms are clearly demonstrated, translation to human physiology is not directly tested in this paper.
Source
Gut microbe-derived extracellular vesicles induce insulin resistance, thereby impairing glucose metabolism in skeletal muscle
Youngwoo Choi et al. · Scientific Reports · 2015
DOI 10.1038/srep15878
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →